Shares in the maker of goods such as Sensodyne toothpaste and Panadol painkillers started trading at 330p, giving the newly-listed business a market capitalisation of £30.5bn and making it the largest London IPO since Glencore’s (LSE: GLEN) offering in 2011.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Still, this isn’t really an apples-to-apples comparison. Unilever would have had to offer Glaxo a premium in order to get it to sell, and it made the offer near the top of the market. Indeed, the S&P Global 1200 Consumer Staples Sector Capped Index (an index of consumer staples stocks) is off around 10% year-to-date.
Saying that, Haleon is now the world’s only listed pure-play consumer health group so it is a bit difficult to find any direct comparisons. The only other public entities with a foot in the market (in developed markets) are Reckitt Benckiser (LSE: RB) and Johnson & Johnson (NYSE: JNJ). J&J is planning its own spinout next year.
A spin off years in the making
Shareholders received one Haleon share for each Glaxo share and the market value of the latter dropped to reflect the reduction in value. However, the remaining group will consolidate its shares to bring the price back inline with its pre-demerger level.
Unfortunately, I wouldn’t be surprised if Haleon’s poor stock performance continues for the rest of the year. There are bound to be a lot of shareholders who would rather own Glaxo, which will have a strong balance sheet and more growth potential after the split due to its focus on vaccines and drugs. That suggests there could be significant selling pressure on the stock as investors rotate from one company to another.
Then there’s the question of Glaxo and Pfizer’s (NYSE: PFE) combined $15bn shareholding. The former joint venture partners have said they will be reducing their holdings when the lock-up ends in November. This could put further pressure on the stock.
Haleon is also starting its life with £10bn of debt and is only expected to see revenue growth of 4% to 6% per annum in the near term. With the stock trading at a forward price-to-earnings ratio of around 20, (based on Barclays’ earnings per share estimate of 16.6p for the current year) it also looks expensive.
Put simply, Haleon’s growth is nothing to shout about, it has two large sellers in the market, a lot of debt and the stock looks expensive.
So what’s to like about the business?
In my view, there are a couple of reasons why investors might want to own this stock (or hold onto the shares they’ve already received).
The consumer healthcare market is one of those sectors that doesn’t generate much excitement, but plays a huge role in our daily lives. Products like Voltaren, a nonsteroidal anti-inflammatory drug, give consumers a cheap and effective way to treat various ailments, for example.
And while it is true there are several cheaper and own-brand competitors out there, when it comes to medications, brands carry much more weight than in any other sector. No one wants to consume medication from an untrustworthy source.
Two key areas of growth for the company are emerging markets and so-called prescription drug “switches.” This is a regulatory process that allows the sale of established prescription drugs as over-the-counter medicines. Voltaren in the US is one of the most recent “switches” and there are more in the pipeline with two planned by 2026.
Producing and selling low-cost medicines at volume is becoming big business, and the market is only likely to grow as the purchasing power of the emerging market consumer expands. According to projections, in India alone, 600m people with $10.5trn of spending power are on the verge of joining the middle class. This is just the sort of growth that will drive top line growth over the next couple of decades.
E-commerce will form a critical part of Haleon’s expansion in these markets. Management wants to grow online sales to a mid-teens percentage of overall sales by the middle of the decade, from a single-digit percentage currently.
These are the three growth drivers that will support Haleon’s expansion in the years to come. The fact that the group is the only way investors can currently invest in the global consumer healthcare market is also notable.
Haleon does not appear to be the best bet in the sector
However, I’m not convinced it’s the best bet on this industry right now.
Before the spin-off, Glaxo’s management declared that Haleon would aim to pay 30% to 50% of its income out as a dividend. Based on current earnings estimates, that suggests a payout of 8.3p a year or a yield of 2.5% on the issue price. It seems unlikely the group will be able to distribute more until it has made a sizable dent in the £10.5bn debt pile that’s been forced on it by Glaxo and Pfizer (both took billions out of the business as dividends before the spin off).
Taking these factors into consideration, I can’t see many reasons to buy Haleon today. The stock looks a bit on the pricey side and its yield leaves a lot to be desired. Reckitt is trading at the same valuation, yields 2.8%, has a growing emerging market business, less debt and a more diversified product portfolio. If I had to pick one of the two, I’d pick the latter.
Disclosure: Rupert Hargreaves owns shares in Reckitt
Rupert was the former Deputy Digital Editor of MoneyWeek. He's an active investor and has always been fascinated by the world of business and investing.
His style has been heavily influenced by US investors Warren Buffett and Philip Carret. He is always looking for high-quality growth opportunities trading at a reasonable price, preferring cash generative businesses with strong balance sheets over blue-sky growth stocks.
Rupert has freelanced as a financial journalist for 10 years, writing for several UK and international publications aimed at a range of readers, from the first timer to experienced high net wealth individuals and fund managers. During this time he had developed a deep understanding of the financial markets and the factors that influence them.
He has written for the Motley Fool, Gurufocus and ValueWalk among others. Rupert has also founded and managed several businesses, including New York-based hedge fund newsletter, Hidden Value Stocks, written over 20 ebooks and appeared as an expert commentator on the BBC World Service.
He has achieved the CFA UK Certificate in Investment Management, Chartered Institute for Securities & Investment Investment Advice Diploma and Chartered Institute for Securities & Investment Private Client Investment Advice & Management (PCIAM) qualification.
Three fund ideas for your stocks and shares ISA
If you have yet to maximise this year’s £20,000 ISA allowance, here are some funds worth considering.
By Katie Williams Published
Holiday scams warning: £12.3m stolen by fraudsters
Action Fraud has revealed thousands of people were hit by holiday scams in 2023. Here's how to protect yourself from fraud.
By Henry Sandercock Published
Halifax: House price slump continues as prices slide for the sixth consecutive month
UK house prices fell again in September as buyers returned, but the slowdown was not as fast as anticipated, latest Halifax data shows. Where are house prices falling the most?
By Kalpana Fitzpatrick Published
Rents hit a record high - but is the opportunity for buy-to-let investors still strong?
UK rent prices have hit a record high with the average hitting over £1,200 a month says Rightmove. Are there still opportunities in buy-to-let?
By Marc Shoffman Published
Pension savers turn to gold investments
Investors are racing to buy gold to protect their pensions from a stock market correction and high inflation, experts say
By Ruth Emery Published
Where to find the best returns from student accommodation
Student accommodation can be a lucrative investment if you know where to look.
By Marc Shoffman Published
Best investing apps
We round up the best investing apps. Looking for an easy-to-use app to help you start investing, keep track of your portfolio or make trades on the go?
By Ruth Emery Last updated
The top funds to invest in
Tips Tech-focused funds are continuing to attract private investors and Scottish Mortgage falls back into favour - we look at the top fund, trusts and stocks investors are pumping their money into in the last month
By Vaishali Varu Last updated
The world’s best bargain stocks
Searching for bargain stocks with Alec Cutler of the Orbis Global Balanced Fund, who tells Andrew Van Sickle which sectors are being overlooked.
By Andrew Van Sickle Published
Revealed: the cheapest cities to own a home in Britain
New research reveals the cheapest cities to own a home, taking account of mortgage payments, utility bills and council tax
By Ruth Emery Published